AP2470A - Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase - Google Patents

Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase

Info

Publication number
AP2470A
AP2470A AP2007003944A AP2007003944A AP2470A AP 2470 A AP2470 A AP 2470A AP 2007003944 A AP2007003944 A AP 2007003944A AP 2007003944 A AP2007003944 A AP 2007003944A AP 2470 A AP2470 A AP 2470A
Authority
AP
ARIPO
Prior art keywords
bcr
inhibitors
abl kinase
phenylaminopyrimidine derivatives
novel phenylaminopyrimidine
Prior art date
Application number
AP2007003944A
Other languages
English (en)
Other versions
AP2007003944A0 (en
Inventor
Amala Kishan Kompella
Kalisatya Adibhatla
Sreenivas Rachakonda
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of AP2007003944A0 publication Critical patent/AP2007003944A0/xx
Application granted granted Critical
Publication of AP2470A publication Critical patent/AP2470A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2007003944A 2004-09-09 2005-07-19 Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase AP2470A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN908CH2004 2004-09-09
PCT/IN2005/000243 WO2006027795A1 (en) 2004-09-09 2005-07-19 Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase

Publications (2)

Publication Number Publication Date
AP2007003944A0 AP2007003944A0 (en) 2007-04-30
AP2470A true AP2470A (en) 2012-09-17

Family

ID=35395645

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003944A AP2470A (en) 2004-09-09 2005-07-19 Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase

Country Status (26)

Country Link
US (2) US7910598B2 (xx)
EP (2) EP1786799B1 (xx)
JP (1) JP5184887B2 (xx)
KR (1) KR100948453B1 (xx)
CN (1) CN101068805B (xx)
AP (1) AP2470A (xx)
AU (1) AU2005281299B2 (xx)
BR (1) BRPI0515081B8 (xx)
CA (1) CA2591321C (xx)
CY (1) CY1113617T1 (xx)
DK (1) DK1786799T3 (xx)
EA (1) EA013328B1 (xx)
ES (1) ES2390227T3 (xx)
HK (1) HK1110588A1 (xx)
HR (1) HRP20070146B1 (xx)
IL (1) IL181811A (xx)
MA (1) MA28922B1 (xx)
MX (1) MX2007002819A (xx)
NO (1) NO337598B1 (xx)
NZ (1) NZ554361A (xx)
PL (1) PL1786799T3 (xx)
PT (1) PT1786799E (xx)
SI (1) SI1786799T1 (xx)
UA (1) UA94570C2 (xx)
WO (1) WO2006027795A1 (xx)
ZA (2) ZA200701942B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2566609C (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US20110190328A1 (en) * 2004-09-09 2011-08-04 Natco Pharma Limited Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CA2591321C (en) 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
WO2008031534A1 (en) * 2006-09-11 2008-03-20 Syngenta Participations Ag Insecticidal compounds
EP2079729A1 (en) * 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors
CL2007003609A1 (es) * 2006-12-14 2008-07-25 Bayer Schering Pharma Ag Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
BRPI0811516A2 (pt) * 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
BRPI0811617A2 (pt) * 2007-05-04 2017-06-06 Irm Llc derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
PL2190825T3 (pl) 2007-08-22 2014-09-30 Novartis Ag Związki 5-(4-(chlorowcoalkoksy)-fenylo)-pirymidyno-2-aminowe i kompozycje jako inhibitory kinazy
ES2368876T3 (es) 2007-08-22 2011-11-23 Irm Llc Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP2011513380A (ja) * 2008-03-04 2011-04-28 ナトコ ファーマ リミテッド フェニルアミノピリミジン誘導体の結晶型
WO2012004801A1 (en) * 2010-07-07 2012-01-12 Hetero Research Foundation Process for imatinib mesylate
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
AU2012302042B2 (en) 2011-09-01 2016-03-31 Novartis Ag Compounds and compositions as c-kit kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
KR20150020683A (ko) * 2012-06-15 2015-02-26 바스프 에스이 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정
EA036513B1 (ru) 2015-12-18 2020-11-18 Натко Фарма Лтд Фармацевтические композиции, содержащие фениламинопиримидиновое производное
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
EP4247368A1 (en) 2020-11-19 2023-09-27 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
CN113125689B (zh) * 2021-03-29 2022-02-22 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2004110452A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (xx) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3588116B2 (ja) 1993-10-01 2004-11-10 ノバルティス アクチェンゲゼルシャフト 薬理活性のピリミジンアミン誘導体およびその製造方法
KR100330553B1 (ko) 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
EP0672035A1 (en) 1993-10-01 1995-09-20 Novartis AG Pyrimidineamine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
HUP0103019A3 (en) * 1998-08-04 2002-01-28 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines, process for producing them and pharmaceutical compositions containing them
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2004002963A1 (ja) * 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
CA2591321C (en) 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
EP2079729A1 (en) * 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2004110452A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors

Also Published As

Publication number Publication date
KR100948453B1 (ko) 2010-03-17
BRPI0515081B1 (pt) 2021-05-04
DK1786799T3 (da) 2012-10-01
BRPI0515081B8 (pt) 2021-05-25
UA94570C2 (xx) 2011-05-25
JP2008512448A (ja) 2008-04-24
EA200700601A1 (ru) 2008-02-28
NO20071521L (no) 2007-06-11
US20070232633A1 (en) 2007-10-04
KR20070106681A (ko) 2007-11-05
HRP20070146A2 (en) 2007-08-31
AP2007003944A0 (en) 2007-04-30
HRP20070146B1 (hr) 2015-12-04
EP2295424A1 (en) 2011-03-16
PL1786799T3 (pl) 2012-12-31
IL181811A (en) 2013-07-31
MA28922B1 (fr) 2007-10-01
WO2006027795A1 (en) 2006-03-16
EA013328B1 (ru) 2010-04-30
CY1113617T1 (el) 2016-06-22
US20080306100A1 (en) 2008-12-11
IL181811A0 (en) 2007-07-04
HK1110588A1 (en) 2008-07-18
US8183253B2 (en) 2012-05-22
EP2295424B1 (en) 2015-10-14
NZ554361A (en) 2009-03-31
EP1786799A1 (en) 2007-05-23
BRPI0515081A (pt) 2008-07-08
MX2007002819A (es) 2007-08-14
US7910598B2 (en) 2011-03-22
SI1786799T1 (sl) 2012-12-31
CN101068805B (zh) 2013-04-03
ES2390227T3 (es) 2012-11-07
CA2591321C (en) 2013-09-24
AU2005281299A1 (en) 2006-03-16
JP5184887B2 (ja) 2013-04-17
ZA200701942B (en) 2008-10-29
PT1786799E (pt) 2012-09-18
CA2591321A1 (en) 2006-03-16
CN101068805A (zh) 2007-11-07
ZA200703123B (en) 2008-10-29
EP1786799B1 (en) 2012-07-04
AU2005281299B2 (en) 2012-03-15
NO337598B1 (no) 2016-05-09

Similar Documents

Publication Publication Date Title
AP2470A (en) Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
ZA200704106B (en) Inhibitors of c-fms kinase
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
HK1090926A1 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
EP1812424A4 (en) Kinase Inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL178968A0 (en) Novel pyridazinone derivatives as inhibitors of cdk2
IL182735A0 (en) Inhibitors of c-fms kinase
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
ZA200700751B (en) Azalndoles useful as inhibitors of protein kinases
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL166180A0 (en) Novel drug compositions based on novel anticholinergies and inhibitors of egfr kinase
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors